In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Key Trends In Immuno-Oncology Dealmaking

Executive Summary

Big Pharma and Mid Pharma companies have signed over 200 immuno-oncology deals in the last five years, creating the most lucrative class in dealmaking, according to a recent Datamonitor Healthcare report. Bristol-Myers Squibb and Merck & Co. have led the charge, and the PD-L1/PD-1 target still dominates.

You may also be interested in...



Seven Key Success Factors In Market Opportunity Assessments

In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.

Solutions Exist To Regenerative Medicine's Most Pressing Manufacturing Challenges

Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.

EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021

Coming year could feature first-time approvals in the EU for at least five gene therapies.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel